Team
Small by design, deep by discipline
Bivalent Bio is led by a team with combined experience across antibody discovery, CMC, clinical development, and biotech operations. We are deliberately small, technically deep, and supported by an advisory network spanning industry and academia.
Leadership
The team building Bivalent Bio
Dr Anna Lindqvist
Chief Executive Officer
Twenty years in antibody discovery and biotech leadership.
Dr Raj Mehta
Chief Scientific Officer
Former head of protein engineering at two clinical-stage biotechs.
Dr Sophie Caron
Chief Development Officer
Translational and clinical development across oncology bispecifics.
James Whitford
Vice President of CMC
Process development and GMP manufacturing leadership.
Scientific Advisory Board
Guided by leaders in the field
- Prof. Eleanor HughesStructural immunology, University of Cambridge.
- Prof. Daniel RothAntibody engineering and protein design, ETH Zürich.
- Dr Mei-Ling TanFormer CSO, clinical-stage oncology biotech.
- Dr Thomas BeckerTumour immunology and translational medicine.
Join the team
We are building a small, senior team of scientists and operators. See our open roles.